When was NewLimit founded?

NewLimit was founded in 2022 and became a unicorn in 2025, reaching the milestone in 3 years. It raised its 1st funding round 1 year after its incorporation.

Where is NewLimit located?

NewLimit is headquartered in San Francisco, United States.

How many employees does NewLimit have?

As of Jun 30, 2026, the latest employee count at NewLimit is 55.

Is NewLimit a funded company?

NewLimit is a funded company, having raised a total of $682M across 4 funding rounds to date. The company's 1st funding round was a $72.2M Series A round, raised on May 08, 2023.

How much is NewLimit worth?

The latest valuation of NewLimit is $3.1B as of Jun 02, 2026.

When was the latest funding round of NewLimit?

NewLimit's latest funding was a $435M Series C round on Jun 02, 2026, with participation from 11 investors.

Is NewLimit a Genomics company?

The primary sector of NewLimit is Genomics.

Where does NewLimit rank among its competitors?

NewLimit ranks 1st amongst 2 active competitors, of which 2 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was NewLimit, which secured $435M in Jun, 2026.

NewLimit - 2026 Company Profile, Team, Funding & Competitors

NewLimit is a series C company based in San Francisco (United States), founded in 2022 by Brian Armstrong and Jacob Kimmel. It operates as a Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension. NewLimit has raised $682M in funding from investors like Founders Fund, Lilly and Kleiner Perkins, with a current valuation of $3.1B.

Sectors and market segments that NewLimit operate in

NewLimit serves in the Life Sciences market segments.The primary business model of NewLimit is:

Life Sciences > Genomics > ***** **** > ***** ******

Company Details

Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension. It focuses on restoring youthful function in old cells by reprogramming the epigenome. The company leverages technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify epigenetic features of aging and discover interventions for rejuvenation. Its initial programs target the aging liver, immune, and vascular systems, with the long-term goal of significantly extending human healthspan through medicines for diseases associated with aging.

Website: www.newlimit.com/
Social

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Series C

Total Funding

$682M in 4 rounds

Latest Funding Round

Series C, Jun 02, 2026, $435M

Post Money Valuation

$3.1B as on Jun 02, 2026

Investors

Founders Fund & 24 more

Ranked

1^st among 2 active competitors

Employee Count

55 as on Jun 30, 2026

Similar Companies

Shift Bioscience

View NewLimit's full profile

NewLimit has raised a total funding of $682M over 4 rounds. Its first funding round was on May 08, 2023. Its latest funding round was a Series C round on Jun 02, 2026 for $435M. 11 investors participated in its latest round. NewLimit has 17 institutional investors and 8 angel investors.

Here is the list of recent funding rounds of NewLimit:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 02, 2026	$435M	Series C	-	-	Founders Fund	Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Valor Equity Partners, Lilly, Human Capital, Nat Friedman, Daniel Gross
Oct 20, 2025	$45M	Series B	$1.6B	-	Lilly	Duke University, S32, Kleiner Perkins, Dimension, Human Capital, Boost VC
May 02, 2025	$130M	Series B	-	-	Kleiner Perkins	Daniel Gross, Khosla Ventures, Founders Fund, Dimension Venture Partners, Garry Tan, Patrick Collison, Human Capital, Valor Equity Partners, Brian Armstrong, Nat Friedman, Elad Gil

Access funding benchmarks and valuations. Sign up today!

View details of NewLimit's funding rounds and investors

The founders of NewLimit are Brian Armstrong and Jacob Kimmel.

Here are the details of NewLimit's key team members:

Brian Armstrong: Co-Founder of NewLimit and founder of 3 other companies, ventures.coinbase.com, Coinbase and Coinbase. They are also an angel investor in 6 startups.
Jacob Kimmel: Co-Founder of NewLimit. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of NewLimit's Founder profiles and Board Members

NewLimit's employee count trend

NewLimit has 55 employees as of Jun 26. Here is NewLimit's employee count trend over the years:

Uncover NewLimit's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NewLimit include Shift Bioscience. Here is the list of Top 10 competitors of NewLimit, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NewLimit 2022, San Francisco (United States), Series C	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$682M	Greenoaks, Founders Fund & 23 others	65/100
2nd	Shift Bioscience 2017, Cambridge (United Kingdom), Seed	Developer of drugs that reprogram mitochondrial (mtDNA) mutations	$28.6M	BGF, galloway & 17 others	59/100